NEW YORK (GenomeWeb News) – Anticipating the expected launch of the Life Technologies' Ion Proton benchtop sequencer, Oppenheimer analyst David Ferreiro today estimated 140 placements of the system in 2012 translating to $35.3 million in revenues.

He added that he estimates 200 placements of Ion Proton in 2013 and 300 placements in 2014, which would result in revenues of $75 million and $150.7 million, respectively.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

The House of Lords in the UK approves a bill to allow mitochondrial donation.